Blog | Page 6 of 34 | Oncotarget

Oncotarget News

Dealing with Runaway Metastatic Disease

August 7, 2024

Metastatic disease remains a major issue in daily practice in oncology because the outcome is still often fatal.”BUFFALO, NY - August 7, 2024 – A new editorial paper was published in... read more

INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death

Oncotarget

INT-1B3 miR-193a-3p Mimic Boosts T Cell Immunity and Induces Tumor Cell Death

August 5, 2024

INT-1B3 inhibited distant tumor metastasis and significantly prolonged survival.”BUFFALO, NY- August 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 12, 2024, entitled, “INT-1B3,... read more

Oncotarget

Prognostic and Therapeutic Insights Into MIF, DDT, and CD74 in Melanoma

July 26, 2024

we present the first study to retrospectively evaluate differential gene expression of MIF, DDT, and relevant pathway markers in regard to clinical outcomes in patients with melanoma.”BUFFALO, NY- July... read more

Oncotarget

Prevalence and Impact of the KIT M541L Variant in Patients With Mastocytosis

July 24, 2024

This study uniquely examines the prevalence and impact of the KIT M541L variant in both adult and pediatric patients with mastocytosis further stratified by disease variant.”BUFFALO, NY- July 24,... read more

Oncotarget

Oncotarget Welcomes New Editorial Board Members

July 22, 2024

Oncotarget is also offering a 50% discount on publication fees until the end of the year.BUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial... read more

Oncotarget

Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC

July 22, 2024

Future development for sEphB4-HSA in HNSCC is likely to focus on patients with HPV-negative disease where there is greatest need to improve on the outcomes with pembrolizumab monotherapy.”BUFFALO, NY-... read more

Oncotarget

DDX41 and Its Unique Contribution to Myeloid Leukemogenesis

July 19, 2024

myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms.”BUFFALO, NY- July 19, 2024 – A new editorial paper was... read more

Oncotarget

Using Early On-treatment Circulating Tumor DNA Measurements as Response Assessment in Metastatic Castration Resistant Prostate Cancer

July 17, 2024

results of Tolmeijer et al. show the promise of on-treatment ctDNA detection as early read out for treatment response to potentially help guide treatment management of patients with mCRPC.”BUFFALO,... read more

Oncotarget

HER2-low and HER2-zero in Breast Cancer Between Prognosis, Prediction and Entity

July 16, 2024

we found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer.”BUFFALO, NY- July 16, 2024 – A new editorial paper was published in Oncotarget's Volume... read more

Oncotarget

Comparison of FDG-PET/CT and CT for Treatment Evaluation of Patients With Unresectable Malignant Pleural Mesothelioma

July 15, 2024

FDG-PET is generally considered as a useful metabolic evaluation tool, while it is also thought to have an emerging role for assessment of systemic therapy response.”BUFFALO, NY- July 15,... read more